APLS
Apellis Pharmaceuticals Inc
3.40$
-0.1%
vs. previous close
Closing price · As of: Aug 13, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +16.2% | +32.6% | +17.7% | +15.9% | -1.4% | +8.0% | -21.5% | +7.0% | +156.9% | -56.4% | +34.2% | – | |
| – | +167.5% | -11.1% | +3.7% | +14.0% | +42.5% | +21.8% | -15.9% | -59.0% | +74.3% | +21.1% | +37.4% | – | |
| – | +1.6% | +43.7% | +19.9% | +16.1% | -7.3% | +5.1% | -22.9% | +24.2% | +164.0% | -60.8% | +33.6% | – | |
| – | -17.0% | -12.8% | +22.3% | -8.0% | +13.6% | -13.8% | +13.2% | -22.5% | +1.7% | +8.9% | +3.7% | – | |
| – | +30.8% | -2.7% | -8.6% | -1.1% | -4.8% | -68.7% | +238.8% | +1.4% | +8.8% | +3.1% | -15.5% | – | |
| – | +8.7% | -6.3% | +1.3% | -3.8% | +2.4% | -6.0% | +9.1% | -8.4% | +6.7% | +5.0% | -9.1% | – | |
| – | – | – | – | – | – | – | – | – | – | -122.9% | – | – | |
| – | -0.4% | +1.3% | -5.9% | +34.3% | +33.9% | -8.0% | -4.2% | +0.9% | +1.1% | -3.8% | -4.9% | – | |
| – | – | – | – | – | – | – | – | – | – | -127.1% | – | – | |
| – | +20.1% | +510.7% | -88.1% | -32.9% | +419.3% | -51.7% | +19.2% | +36.7% | +29.2% | -48.0% | +58.5% | – | |
| – | – | – | – | – | – | – | – | – | – | -127.3% | – | – | |
| – | – | – | – | – | – | – | – | – | – | -120.8% | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: August 13, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.